Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung
August 20, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced the appointment of Winston Kung to its Board of...
Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 06, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Clinical update presented at ASCO 2024 for CRB-701 showed continued differentiated safety and encouraging efficacy in patients with metastatic urothelial cancer or cervical cancerCRB-701 Phase 1 dose...
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August
July 30, 2024 08:50 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer...
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
June 01, 2024 10:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacySYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and...
Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
May 30, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of...
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
May 23, 2024 17:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that the abstract [No. 3151] for a poster...
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
May 09, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of...
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024 $116M of capital raised in Q1 2024 extending cash runway through Q1 2027 Appointed Dr. Dominic...
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
May 01, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of...
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
April 24, 2024 16:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that an abstract providing updated data from the...